In breast cancer, low levels of CRISP3 in tissue are correlated with poor survival rates53, whereas in ovarian cancer, increased expression of CRISP3 in serum is associated with HGSOC and poorer survival outcomes (Fig. 4d). This evidence concerns the gene CRISP3 and ovarian cancer.